All In Biotech

Drug Trial Radar · NCT06891833

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 985 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

985

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controlled study phase (Phase III).

Conditions

  • HER2-positive Breast Cancer

Interventions

  • BL-M07D1Drug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • PertuzumabDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • docetaxelDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • carboplatinDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • trastuzumabDrug

    Administration by intravenous infusion for a cycle of 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) rateTime frame: Up to approximately 48 months

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

    Hefei, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Guangdong Maternal and Child Health Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen, Guangdong, China · Not yet recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Hainan General Hospital

    Haikou, Hainan, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Anyang Cancer Hospital

    Anyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of science and technology

    Luoyang, Henan, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Shaanxi Provincial People's Hospital

    Xi'an, Shaanxi, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.